Rationale: Atherosclerosis is a widespread and devastating disease, but the origins of cells within atherosclerotic plaques are not well defined.
A therosclerosis leads to myocardial infarction and stroke and is the major cause of death in the Western world. It is a chronic inflammatory condition that results from complex interactions of modified lipoproteins and various cell types, including monocyte-derived macrophages and cells of the vessel wall. [1] [2] [3] How each particular cell type contributes to the development of an atherosclerotic lesion is not completely understood. [4] [5] [6] [7] One unsolved issue is the role of mature smooth muscle cells (SMCs) that reside in the vascular media. 8, 9 It is generally accepted that vascular SMCs are not terminally differentiated and can undergo phenotypic transitions during lesion development. However, this concept is mainly based on in vitro results with cultured SMCs and conclusive in vivo studies that have assessed the contribution of SMC plasticity to the development of cells with alternative phenotypes within atherosclerotic plaques are lacking. 5, 8 Two previous studies found by immunostaining of human plaque sections that some intimal cells coexpressed markers of SMCs and macrophages, suggesting the existence of a SMC-macrophage chimeric cell type in human lesions. 10, 11 However, these experiments did not allow one to determine the origin of the chimeric cells (ie, whether they originated from SMCs, macrophages, or other cell types). Furthermore, these studies were based on the staining of plaque cells for the classic SMC marker, smooth muscle α-actin (SMA), and did not allow the detection of potential SMC-derived plaque cells that have lost SMA expression. To evaluate the role of SMC plasticity in atherogenesis, there is a critical need for definitive in vivo SMC lineage tracing studies. 5, 8 Editorial, see p 605 In This Issue, see p 601
Methods
Genetic inducible fate mapping of medial SMCs was performed in apolipoprotein E (ApoE)-deficient mice carrying a SMC-specific tamoxifen-activated Cre recombinase and Cre reporter alleles expressing β-galactosidase or fluorescent proteins. For details on experimental animals, detection of reporter gene expression, immunostaining, and electron microscopy, an expanded Methods Section is available in the Online Data Supplement.
Results
To track the fate of medial SMCs during atherogenesis in mice, we have used a Cre/lox-based genetic inducible fate mapping
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to Macrophage-Like Cells During Atherogenesis system previously established by us. 12, 13 Experimental animals were ApoE-deficient (ApoE −/− ) 14 and carried transgenes encoding the tamoxifen-dependent CreER T2 recombinase integrated into the endogenous SM22α gene locus (SM22-CreER T2 ), which is selectively expressed in SMCs of adult mice, 15 and the well-characterized ROSA26 Cre reporter allele (R26R), which on Cre-mediated recombination can express β-galactosidase in a wide array of cell types and tissues. 16 The Cre-activated R26R allele is inherited to all progeny cells, so that the fate of the originally labeled cells can be followed by staining tissues with 5-bromo-4-chloro-3-indolyl β-dgalactoside (X-Gal) for β-galactosidase activity.
We pulse-labeled medial SMCs before the development of atherosclerosis by injecting 10-week-old mice for 5 consecutive days with tamoxifen. X-Gal staining of aortic sections 1 week after the last tamoxifen injection showed that this protocol resulted in sparse labeling of 11±1% SMCs in the aortic media ( Figure 1A ), allowing also for clonal analyses of cell fate. It was important to exclude ectopic labeling of non-SMCs that might have expressed the SM22α-driven CreER T2 recombinase during the labeling period and could potentially contribute to future plaque development, for instance, progenitor cells in the adventitia or bone marrow. 6, 17 However, our induction protocol did not result in labeling of cells in the adventitia ( Figure 1A) , and even after prolonged tamoxifen treatment for 10 days to increase the labeling efficiency, we did not detect any X-Gal-positive cells in the aortic adventitia and circulating blood cells ( Figure 1B ) or in bone marrow cells ( Figure 1C , top). Moreover, virtually all X-Gal-positive cells also stained positive for the smooth muscle differentiation marker, smooth muscle myosin heavy chain ( Figure 1D ). The latter finding confirmed that we labeled mature differentiated SMCs in our model, but not presumptive vascular stem cells that might also reside in the vascular media and are smooth muscle myosin heavy chain negative. 18 Next, we analyzed the fate of medial SMCs in 52-weekold ApoE −/− mice that were fed with a normal chow. X-Gal staining of atherosclerotic aortas revealed few labeled cells in the media and, interestingly, occasional large patches of labeled cells that were invariably located within atherosclerotic lesions and sometimes covered the entire intimal area of the plaque section ( Figure 1E and 1F). These findings indicated that each continuous X-Gal-positive cell patch was derived by clonal expansion of an individual medial SMC that was originally labeled by tamoxifen treatment in the 10-week-old animal. Clonal SMC-derived plaque areas were observed in 19 of 22 analyzed mice (86%). Similar results were obtained in ApoE −/− mice that received a high-fat diet (20% fat, 1.5% cholesterol by weight) for 16 weeks after the last tamoxifen injection, with 8 of 12 analyzed mice (67%) showing SMC-derived cell patches within lesions. The existence of clonally grown SMC-derived lesional regions was further established using 2 alternative fluorescence-based Cre reporter alleles. The R26R-mT/mG reporter 19 expresses membrane-tagged red and green fluorescent protein before and after Cre-mediated activation, respectively ( Figure 1G ). The R26R-Confetti multicolor Cre reporter 20 expresses stochastically 1 of 4 fluorescent marker proteins generating nuclear green, cytoplasmic yellow, cytoplasmic red, or membrane-bound blue cells, which makes this reporter allele particularly useful for clonal tracing analysis of individually labeled SMCs ( Figure 1H ).
To exclude potential pitfalls of our cell tracing strategy, several additional control experiments were performed. Plaque sections prepared from X-Gal stained aortas of nontamoxifentreated mice did not show blue-stained cells (Online Figure  IA) , indicating that our labeling system was not leaky in the absence of tamoxifen and that the X-Gal staining observed in tamoxifen-treated animals ( Figure 1A-1F ) was specific. The specificity of signals that were detected in whole mount preparations of the tamoxifen-induced fluorescence-based Cre reporter mice ( Figure 1G and 1H) was controlled by comparison with tissues from nontamoxifen-treated mice (Online Figure  IB) and by fluorescence microscopy of thin sections prepared from whole mounts of tamoxifen-treated mice (Online Figure  IC) . Furthermore, immunostaining of aortic sections showed that cells in the aortic media did not express MAC-2 (also known as Galectin-3 or LGALS3), which is expressed in macrophages (Online Figure ID) . Finally, cells from aorta, plaque, peripheral blood, and spleen of R26R-mT/mG reporter mice were analyzed by flow cytometry (Online Figure II) . We did not detect green fluorescent-labeled cells in tissues from nontamoxifen-treated mice. Tamoxifen treatment induced the appearance of green fluorescent cells in aorta and in plaque but not in peripheral blood or spleen (Online Figure IIA-IID) . In particular, we did not detect labeled Gr-1 + neutrophils or monocytes (Online Figure IIE-IIG) .These findings confirmed that our inducible fate mapping system was not leaky and that the green fluorescence observed in whole mounts, sections, and cells of plaques from tamoxifen-induced R26R-mT/mG mice ( Figure 1G ; Online Figures IC and IIB) was specific and not because of autofluorescence. Importantly, our extensive control experiments did not reveal any evidence that myeloid cells in the blood and spleen were ectopically labeled during the tamoxifen pulse. This finding is also in agreement with a previous report, showing that the SM22-CreER T2 transgene used in our study is not expressed in hematopoietic stem cells of adult mice. 21 Formally, it might be conceivable that the X-Gal-positive or green fluorescent lesional cells originated as monocyte-derived macrophages that had phagocytized labeled SMCs. However, this possibility is highly unlikely for ≥2 reasons. First, the upregulation of macrophage markers is also observed in cultured SMCs that presumably do not contain monocytes/macrophages. 22 Second, the biological activity of the reporter proteins that is required for detection of the labeled cells (ie, enzymatic β-galactosidase activity or green fluorescence) would most likely not be preserved after phagocytosis of the SMC.
Immunostaining of X-Gal-stained plaque sections showed that, as expected, cells in the media and fibrous cap strongly expressed SMA (Figure 2A and 2B) . In contrast, the SMCderived cells in the intima were either not stained for SMA or expressed it at a much lower level than SMCs in the media or fibrous cap ( Figure 2B ). Weak staining for SMA was detected in 39±5% of X-Gal-positive intimal cells. Thus, it is likely that the SMC-derived intimal cells went undetected in previous studies that analyzed the contribution of SMCs to lesion development by immunostaining for SMA. Interestingly, the majority of the SMC-derived cells in the intima stained positive for 2 markers that are commonly used to detect macrophages in plaque sections, MAC-2 (62±4% of X-Gal-positive intimal cells; Figure 2C ) and CD68 (54±4% of X-Gal-positive intimal cells; Figure 2D) . A macrophage-like function of the SMC-derived plaque cells was further supported by positive staining for oxidized low-density lipoprotein (81±2% of X-Gal-positive intimal cells; Figure 2E ), as well as by electron microscopic studies, which showed a foam cell-like morphology of the X-Gal-positive intimal cells (Figure 2F , middle). However, the SMC-derived cells contained significantly less lipid droplets than X-Gal-negative classical foam cells ( Figure 2F , lower; 7±1 droplets/cell; n=48 cells versus 29±3 droplets/cell; n=26 cells; P<0.001).
Discussion
On the basis of these in vivo findings, we propose that mature medial SMCs can undergo clonal expansion and transdifferentiate to macrophage-like cells during the development of atherosclerotic lesions. This model is consistent with reports showing that (1) cultured mouse and human aortic SMCs can gain a macrophage-like phenotype in vitro that is characterized by decreased expression of SMC markers, upregulation of macrophage markers, and increased phagocytic activity, 22, 23 (2) a large fraction of intimal MAC-2-positive cells in murine plaques is not derived from bone marrow progenitors, 12, 24 and (3) many cells within human atherosclerotic lesions express both SMA and CD68. 10, 11 Our observation that not all X-Gal-stained cells in the intima expressed macrophage markers ( Figure 2C and 2D) is consistent with the SMCto-macrophage transdifferentiation process. Alternatively, these cells could represent other SMC-derived cell types, such as chondrocyte-like cells. 25, 26 Because of the fact that only few medial SMCs were initially genetically labeled in the 10-week-old animal, we cannot draw conclusions about the origin of plaque cells that were not stained positive with X-Gal. Considering our sparse labeling strategy and the high proportion of macrophage-like X-Gal-positive cells in the stained plaques, it seems that SMC-derived macrophages, in addition to conventional monocyte-derived macrophages, represent a significant component of advanced atherosclerotic lesions in ApoE-deficient mice. In this context, it is interesting to note that Robbins et al 27 have recently reported that monocyte recruitment cannot fully account for lesional macrophage accumulation in established atherosclerosis. It is possible that the plaque macrophages detected by Robbins et al 27 were derived from few bone marrow monocytes that proliferated after recruitment to the lesion. However, alternative mechanisms should not be excluded, for instance, that certain plaque macrophages/macrophage-like cells originate and are maintained independently of monocyte input. Indeed, recent evidence shows that monocytes do not substantially contribute to most tissue macrophage populations in the steady state or during certain types of inflammation. 28 To characterize the SMC-derived plaque macrophages further, we compared the expression of selected proteins in nonatherosclerotic aorta versus cultured aortic SMCs, which undergo phenotypic changes during in vitro culture that might also occur in vivo during SMC-to-macrophage transdifferentiation. 29 Indeed, in line with previous in vitro results 22 and our in vivo data, Western blot analyses demonstrated downregulation of SMA and smooth muscle myosin heavy chain and upregulation of MAC-2 and CD68 in cultured SMCs when compared with nonatherosclerotic aorta ( Figure 3A) . Other proteins that we found to be upregulated in cultured SMCs ( Figure 3B -3E, left) were proliferating cell nuclear antigen, heme oxygenase-1, thrombospondin-1, and hypoxia-inducible factor-1α, all of which are associated with cell growth and stress. Importantly, these proteins were also expressed in the SMC-derived intimal plaque cells in vivo ( Figure 3B-3E ). Proliferating cell nuclear antigen, heme oxygenase-1, thrombospondin-1, and hypoxia-inducible factor-1α were detected in 24±3%, 60±3%, 69±6%, and 86±3% of X-Gal-positive intimal cells, respectively. However, the SMC-derived cells did not stain for markers of M1 or M2 macrophages, inducible nitric oxide synthase or arginase-1, respectively (data not shown). Intriguingly, heme oxygenase-1 and thrombospondin-1 have been recently described as markers for the Mox macrophage subtype 30 that, consistent with our electron microscopy data ( Figure 2F) , has a lower phagocytic capacity than M1 or M2 macrophages. Mox macrophages develop in response to oxidative tissue damage and may play an important role in atherosclerosis. 7, 30 Additional studies are required to understand the mechanism of this type of SMC phenotypic modulation fully, as well as the functionality and pathological relevance of SMC-derived versus monocyte-derived plaque macrophages. Indeed, combined gene targeting and cell tracking indicates that it is possible to modulate atherogenesis by targeting SMC-to-macrophage transdifferentiation. 12, 13 It will be interesting to perform similar inducible fate mapping experiments with monocytederived plaque cells. Then, both SMC-derived and monocyte-derived intimal cells could be isolated from plaques and comparatively characterized, for instance, by thorough gene expression profiling.
Taken together, this study highlights the heterogeneity of both SMCs and macrophages in atherosclerotic lesions and provides strong in vivo evidence for a major role of SMC plasticity in atherogenesis. According to our new model, mature SMCs that are present in the media of the nonatherosclerotic vessel wall possess the potential to become activated during plaque development and transdifferentiate to macrophage-like cells with a Mox phenotype that reside within the lesion. The SMC-derived plaque macrophages have a clonal origin in the vascular media and can make up a major fraction of the intimal cells. These findings indicate that previous studies that were based on immunostaining of plaque cells for smooth muscle markers have vastly underestimated the role of SMC plasticity in atherosclerosis and, because SMCs are present in almost every tissue, possibly in many other diseases, including hypertension, lung injury, liver injury, and cancer. Targeting SMC-to-macrophage transdifferentiation could be a novel therapeutic strategy to treat these diseases.
